First-Line Lorlatinib vs Crizotinib in ALK-Positive Advanced NSCLC
This was a planned interim analysis of a phase 3 study comparing lorlatinib and crizotinib as a frontline treatment for patients with ALK-positive NSCLC.
Lung Cancer
Osimertinib Found to Reduce Risk of CNS Recurrence in Resected EGFRm NSCLC
Analysis suggests osimertinib lowers the risk of CNS recurrence in patients with completely resected EGFR-mutated NSCLC.
Capmatinib Shows Clinical Activity in MET Exon 14–Mutated NSCLC
Capmatinib showed clinical activity in patients with MET exon 14–mutated advanced non–small cell lung cancer, reported a phase 2 trial.
Study Documents Real-World Survival Improvement for Non-Small Cell Lung Cancer
An analysis finds that mortality rates for NSCLC are falling faster than incidence rates, which the authors attributed to the introduction of targeted therapies in 2013.
Expertscape Publishes Top 10 Specialists in Lung Cancer
Expertscape, a platform for discovering physicians excelling in the treatment and diagnosis of specific disease states, has released their rankings for US physicians who specialize in lung cancer. Using Expertscape’s patented algorithm, Suresh Ramalingham, MD, of Emory University in Atlanta, Georgia, topped the list. Among his many publications in 2020, Ramalingham published a paper on…
Is the Increase in Teen Vaping Affecting Lung Cancer Rates?
E-cigarette use among teens and young people has been a medical concern ever since the product hit the market. By 2018, the US Surgeon General had referred to vaping as an “epidemic,” and the US Food and Drug Administration has spent years working to regulate the e-cigarette industry to try and curtail use. Even still,…
How to Improve LDCT Screening Rates in Persons at High Risk of Lung Cancer
Nurses working in primary care settings are well-situated to identify and educate patients at high risk of lung cancer who are eligible to undergo LDCT screening.
Gavreto Approved for Metastatic RET Fusion-Positive NSCLC
The FDA has approved Gavreto™ (pralsetinib; Blueprint Medicines and Genentech) for the treatment of adults with metastatic RET fusion-positive NSCLC.
Comparative Analysis of Pembrolizumab or Nivolumab in NSCLC
Although PFS was similar with both agents, a single-center retrospective comparative analysis found that pembrolizumab was associated with a higher ORR vs nivolumab in NSCLC.
Are SMARCA4 Alterations in NSCLC Associated With Poor Outcomes With ICIs?
NSCLC harboring SMARCA4 alterations without STK11/KEAP1 mutations was not associated with poor outcomes with ICI treatment in a retrospective study.
-
Loading...
-
Loading...
Next post in Lung Cancer
